heart disease in pregnancy
CO ↑30–50% (peaks late T2), HR ↑, SVR ↓ → stenotic lesions and pulmonary hypertension tolerated poorly; regurgitant lesions well. Highest-risk window = labour and the first 24–72 h postpartum (autotransfusion). mWHO 2.0 class II–III or higher → Pregnancy Heart Team from pre-conception (ESC 2025). Mechanical valves are the exception to “no warfarin in pregnancy”. Don’t withhold cardioversion or PCI because of pregnancy; valve surgery only if maternal life at risk and other options fail.
normal vs abnormal
| normal in pregnancy | never normal |
|---|---|
| resting HR ↑10–20, palpitations, mild exertional dyspnoea | hypoxaemia, resting dyspnoea, PND |
| soft systolic ejection murmur (≤2/6), S3, venous hum | diastolic murmur, loud/harsh systolic murmur |
| displaced apex, mild oedema, mildly ↑JVP | syncope on exertion, chest pain, progressive orthopnoea |
| ECG: left axis shift, small Q in III, T inversion III/V1–2 | sustained arrhythmia, new conduction disease |
| NT-proBNP normal (no pregnancy-specific cut-off; strong NPV) | NT-proBNP clearly raised |
risk stratification — mWHO 2.0 (ESC 2025)
| class | IM-relevant examples | care |
|---|---|---|
| I–II | isolated ectopics, most SVTs, repaired simple shunts, mild PS/MVP | local hospital |
| II–III | EF >45%, HCM without complications, mild MS, moderate AS, moderate regurgitation, Marfan without dilatation, BAV aorta <45 mm | shared care + Pregnancy Heart Team |
| III | EF 30–45%, mechanical valve, prior PPCM with ≤ mild residual impairment, prior SCAD or ACS, prior adverse pregnancy outcome needing admission, prior cancer-therapy cardiotoxicity, moderate MS, severe asymptomatic AS, sustained VT, Marfan aorta 40–45 mm | expert centre, Pregnancy Heart Team-led |
| IV — contraindicated | PAH, EF <30% or NYHA III–IV, prior PPCM with > mild residual impairment, severe MS, severe symptomatic AS, Marfan aorta >45 mm (BAV >50 mm), vascular EDS, Eisenmenger | advise against; shared decision on termination |
Congenital lesions (Fontan, systemic RV, cyanotic CHD) → full table in the guideline; all need adult CHD/cardio-obstetrics.
Pre-pregnancy: TTE ± exercise test for all with known/suspected structural disease; intervene on symptomatic severe stenosis before conception (ACC/AHA I).
valve lesions
| lesion | problem | management |
|---|---|---|
| mitral stenosis | ↑HR shortens diastole → ↑LA pressure → pulmonary oedema, AF | β1-blocker (metoprolol), cautious diuretic; AF → rate control + anticoagulation; refractory severe → percutaneous balloon commissurotomy; valve area <1.5 cm² → intervene before pregnancy |
| aortic stenosis | fixed LVOT — can’t raise CO; preload-dependent | avoid hypovolaemia and abrupt SVR drop (careful neuraxial); severe symptomatic despite medical therapy → BAV/TAVI may be considered (very selected); symptomatic severe AS → intervene before pregnancy |
| MR / AR | ↓SVR reduces regurgitant fraction | usually tolerated; diuretics if congested |
- Delivery: vaginal + early epidural for most; CS for obstetric indications, aortic disease, or anticoagulated on VKA in labour
- See valvular heart disease, aortic stenosis, prosthetic heart valves
mechanical valves (AHA/ACC 2020, ESC)
Thrombotic complications 9–24%, bleeding 20–30%; event-free pregnancy with live birth only ~55–58%. Young women needing a prosthesis and contemplating pregnancy → bioprosthetic preferred. Cardio-obstetrics centre only.
| warfarin dose | T1 (6–12 wk) | T2–T3 |
|---|---|---|
| ≤5 mg/d | continue warfarin (IIa) or LMWH | warfarin |
| >5 mg/d | dose-adjusted LMWH BID (IIa) | warfarin (or LMWH) |
- LMWH: BID, anti-Xa 0.8–1.2 U/mL at 4–6 h (peak); trough monitoring too in many centres — fixed-dose LMWH is unsafe
- Warfarin embryopathy dose-dependent (low risk at ≤5 mg/d); continue warfarin until pregnancy confirmed, switch before 6 wk if plan is LMWH
- Delivery: switch VKA → LMWH/IV UFH at 36 wk or ≥2 wk before planned delivery; LMWH → IV UFH ≥36 h before; stop UFH ≥4–6 h before; labour on VKA → caesarean after reversal (foetal ICH risk)
- Postpartum: restart UFH/LMWH at 6–12 h ; start warfarin only from 7–14 days (late bleeding) — breastfeeding-compatible
- Valve thrombosis: TTE/fluoroscopy; obstructive → thrombolysis or surgery
arrhythmias
| rhythm | management |
|---|---|
| PVCs / PACs | common; reassure if low burden + normal echo; symptomatic or high burden → metoprolol or bisoprolol; check CBC, ferritin, K⁺/Mg²⁺/Ca²⁺, TSH |
| SVT | vagal → adenosine (safe) → β1-blocker or verapamil; prophylaxis with metoprolol; DCCV if unstable |
| AF/flutter | look for MS, thyrotoxicosis, CHD; rhythm control preferred — DCCV safe in all trimesters (foetal monitoring); rate control β-blocker ± digoxin; anticoagulate per CHA₂DS₂-VA (not validated in pregnancy) with LMWH |
| VT | DCCV if unstable; β-blocker; sotalol/flecainide if needed; avoid amiodarone (foetal thyroid) unless life-threatening and refractory |
| AV block | usually congenital/structural; delivery vagal surges → monitor in labour |
- Cardioversion and defibrillation are safe at all stages (pads anterolateral, left uterine displacement)
- Labetalol is an antihypertensive, not an antiarrhythmic of choice
- Anticipate β-blocker down-titration postpartum (HR/BP fall)
10% PVC burden, normal echo, symptomatic → metabolic labs, then metoprolol (or bisoprolol). Avoid atenolol (FGR) and amiodarone (foetal hypothyroidism); labetalol is for BP.
syncope
- Vasovagal/orthostatic common (↓SVR, IVC compression)
- Exertional, prolonged, or with palpitations/chest pain → ECG + echo; consider PE, arrhythmia, haemorrhage (abruption, ectopic early), AS/HCM/PAH
other
- ACS: SCAD is the leading cause of pregnancy-associated MI (peripartum) — conservative if stable; ASA, β-blocker; PCI with radial access if ongoing ischaemia — see spontaneous coronary artery dissection
- Aortic dissection: Marfan, Loeys–Dietz, bicuspid aortopathy, Turner, vEDS; β-blocker throughout; type A → surgery (with CS if viable)
- Statins: FDA removed pregnancy contraindication (2021) — continue only in very high risk (FH, recent ACS) after discussion; stop for primary prevention ~3 months before conception; avoid in breastfeeding
- Endocarditis prophylaxis: not routine for delivery; may be considered in high-risk women (ESC IIb)
ACEi, ARB, ARNI, MRA, SGLT2i, ivabradine, amiodarone (except life-threatening), atenolol, DOACs, warfarin (except mechanical valves), statins (most), endothelin antagonists. Full table → prescribing in pregnancy and lactation.
Prepared 2026-10-19. Not yet verified — check every number against the sources.